TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Cellenkos® Collaborates with Icahn School of Medicine at Mount Sinai, New York, in Sponsored Research Agreement

Monday, April 01, 2024

Cellenkos®, a biotech company in the clinical stage, focused on developing cell therapy treatments for autoimmune diseases and inflammatory disorders, has announced a collaborative research agreement with the Icahn School of Medicine at Mount Sinai, New York. The aim is to explore the potential of CK0804, a type of allogeneic cord blood T regulatory (Treg) cells enriched with CXCR4, for treating myelofibrosis. This research will be overseen by Dr. Ronald Hoffman, who is the Albert A. and Vera G. List Professor of Medicine and Director of the Myeloproliferative Disorders Research Program at The Tisch Cancer Institute at Mount Sinai.

"We're thrilled about our partnership with Mount Sinai and look forward to delving deeper into how CK0804 Tregs function in myelofibrosis, particularly in reducing inflammation," said Tara Sadeghi, Chief Operating Officer of Cellenkos Inc. "CK0804 is already undergoing phase 1 clinical trials to assess its safety and effectiveness in myelofibrosis patients who have not responded well to the JAK2 inhibitor, ruxolitinib. We're particularly interested in exploring the potential of using CK0804 in treatment-naïve myelofibrosis patients and in combination with other approved therapies, including ruxolitinib, momelotinib, pacritinib, and fedratinib."

"We're eager to determine if this innovative cell therapy product could revolutionize the treatment of myelofibrosis patients," said Dr. Ronald Hoffman, the principal investigator. "We'll be investigating the role of Treg cells in the development of myeloproliferative neoplasms and assessing the efficacy of CK0804, especially in patients with low blood counts."

CK0804 is a novel allogeneic Treg cell therapy product enriched with CXCR4, developed using Cellenkos' proprietary CRANE® technology to produce disease-specific products. CK0804 interacts with the CXCL12 ligand and selectively targets the inflamed bone marrow. In vivo studies have shown that compared to controls, CK0804 significantly reduces levels of TGFβ1 and TGFβ2. The ongoing phase 1b trial, conducted at multiple centers, demonstrates the safety of multiple doses of CK0804 in myelofibrosis patients in outpatient settings, as well as improvements in blood transfusion requirements, reduction in spleen volume, and alleviation of symptoms. The ability to administer CK0804 cells in outpatient settings without requiring lymphodepletion or immune suppression makes this potentially life-saving treatment accessible to patients in the community. The trial is currently open for enrollment at Albert Einstein Hospital in Bronx, NY, MD Anderson Cancer Center in Houston, TX, and University of California Davis in Sacramento.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement SummitHealthcare Innovation & Transformation Summit